National obstetrics and gynecology professional association and 501(c)(6)
One uniform surface for comparison; detailed evidence is below.
The score summarizes assessed evidence; evidence coverage is reported separately.
Six Form 990 revenue categories reconcile exactly. Accounting categories do not disclose who paid for dues, publications, meetings, education, grants, royalties, sponsorships, or services.
| Accounting category | Amount | Share |
|---|---|---|
| Program services | $44.02M | 69.32% |
| Contributions and grants | $13.26M | 20.88% |
| Royalties | $3.20M | 5.03% |
| Investment income | $1.64M | 2.59% |
| Other revenue | $864,729 | 1.36% |
| Sales of assets | $516,107 | 0.81% |
| Total | $63.51M | 100.00% |
A conservative minimum identifies $6.5 million in government grants, a $1.5 million ACOG Foundation grant, and a $14,000 health-system grant. The residual is unattributed by payer class, not evidence of hidden or improper support.
Primary constituency: Individual obstetrician-gynecologist Fellows, trainees, and other professional member categories; corporate or group membership is not the formal governance model.
Physician alignment: Generally supportive for obstetrician-gynecologists; role and issue alignment is less direct for other physicians.
Funding model: Program-service led with material grants, royalties, and investment income; payer identity is mostly not public.
Primary influence: Voting Fellows and the Board formally; CEO and executive staff operationally; government, foundation, commercial, and institutional supporters are documented without a dominant payer classification.
ACOG is an individual-member obstetrics and gynecology professional society with physician officers, district representation, trainee pathways, a governing Board, and a physician CEO. FY2024 revenue was $63.51 million, dominated by program services and contributions and grants. The organization’s clinical guidance, education, coding, workforce, maternal-health, and professional advocacy record is strongly aligned with its stated constituency. Public records, however, identify the ultimate payer class for only a conservative minimum of 12.6%; employer-paid dues, royalty counterparties, sponsorship amounts, and customer concentration remain unknown. The provisional C grade therefore reflects financial-source and accountability gaps rather than a conclusion that ACOG is poorly aligned with obstetrician-gynecologists.
One sentence: ACOG appears genuinely physician-governed and strongly aligned with ob-gyn practice, while incomplete payer-source and commercial-term disclosure keeps its evidence and accountability grade provisional.
Every organization uses the same twelve evidence sections and order.
The legal entity is the American College of Obstetricians and Gynecologists, EIN 90-0489809, an active District of Columbia 501(c)(6) professional association. ACOG traces its professional history to 1951; the current tax-exempt legal entity is reported as formed in 2009.
ACOG describes itself as the leading professional membership organization for ob-gyns, with more than 62,000 members, clinical guidance, education, practice tools, and advocacy for equitable, evidence-based care.
| Constituency type | Evidence-based conclusion | Confidence |
|---|---|---|
| Formal constituency | Individual professional members, centered on board-certified ob-gyn Fellows and ob-gyn trainees; other physicians and related professionals may join in noncore categories. | High |
| Paying constituency | Members, employers/training programs that may reimburse dues, purchasers of education/publications/services, grantmakers, sponsors, advertisers, exhibitors, licensees, and investment assets. Exact shares are not public. | Moderate |
| Operational constituency | Programs and advocacy predominantly address ob-gyn professional practice and patients needing obstetric and gynecologic care. | High |
| Beneficiaries and reach | Ob-gyns, trainees, other clinicians, hospitals/care teams, patients, and the public may benefit without necessarily governing or funding ACOG. | High |
77th President; inaugurated May 3, 2026. The elected president leads the professional and governance agenda but is not the day-to-day operating executive.
Chief Executive Officer since August 5, 2024. The leadership team supports the Board and oversees day-to-day operations.
Current roster includes national officers, 12 district chairs, Fellow-at-large, Junior Fellow leaders, early-career members, a public member, and the CEO.
| Current leader | Role | Authority or relevance | Public compensation note |
|---|---|---|---|
| Camille A. Clare, MD, MPH, CPE | President | Elected physician leader and Board officer. | FY2024 filing predates presidency; current compensation not established. |
| May Hsieh Blanchard, MD | President Elect | Successor in elected leadership pathway. | Current amount not established. |
| Cole Douglas Greves, MD, MBA | Treasurer | Board financial oversight. | Current amount not established. |
| Lisa M. Foglia, MD | Secretary | Board governance and records. | Current amount not established. |
| Sandra E. Brooks, MD, MBA | CEO | Principal operating authority; Board member. | FY2024 reportable compensation $216,885 plus $82,437 other compensation for a partial year; not current annualized pay. |
| Rob Batarla, MBA, CPA | Chief Financial Officer | College/Foundation finance; PAC treasurer. | FY2024 reportable compensation $341,536 plus $85,895 other. |
| Molly Meegan, JD | Chief Legal Officer | Legal, policy, advocacy, and compliance oversight. | FY2024 reportable compensation $354,105 plus $96,985 other. |
| Jennifer Walsh | Chief Operating Officer | Publishing, products, membership, meetings, technology, and strategic revenue operations. | FY2024 reportable compensation $229,404 plus $107,074 other. |
| Christina Davidson, MD, FACOG | Chief Medical Officer | Clinical guidance, quality improvement, and clinical practice; joined June 2026. | Not available in FY2024 filing. |
$63.28M expenses; $227,182 surplus; $93.21M assets; $69.55M net assets.
Likely includes multiple member and customer activities, but the return does not identify who paid most of it.
The public filing shows the change but not the contracts, counterparties, or reason.
| Support source | FY2024 finding | Assessment |
|---|---|---|
| Individual membership dues | Membership dues are charged, but the filing/public pages reviewed do not separate total dues or personally paid dues. | Unknown |
| Employer/training-program paid dues | ACOG actively encourages use of employee benefits/CME allowances and provides employer payment templates; percentage unknown. | Potential influence channel |
| Government grants | $6.5M reported in FY2024; ACOG later stated it withdrew from all federal funding in 2025. | Changed after filing |
| ACOG Foundation | $1.5M named grant to the College in FY2024. | Directly documented |
| Hospital/health system | $14,000 named grant from Adventist Health System Sunbelt; total hospital/system payments cannot be determined. | Minimum only |
| Royalties | $3.20M, or 5.0% of revenue. | Counterparties not public |
| Advertising/exhibits/sponsorship | Programs and policies are public; amounts and concentration are not comprehensively reconciled. | Relationship documented |
| Investment income | $1.64M; marketable securities represented a large share of assets. | Diversifying source |
Publicly identifiable minimum: approximately $8.014 million, or 12.6% of FY2024 operating revenue, can be assigned to named payer/supporter classes using government-grant disclosure and named grants. Approximately $55.492 million, or 87.4%, cannot be attributed to an ultimate payer class from the public records reviewed.
Cannot be calculated. The report therefore classifies financial-influence concentration as indeterminate, not high.
No public data were found showing the number or dollar share of memberships paid directly by physicians, employers, health systems, groups, or training programs.
| Entity/channel | Legal/operational distinction | Current evidence | Do not infer |
|---|---|---|---|
| ACOG operating entity | 501(c)(6) professional association, EIN 90-0489809. | FY2024 revenue $63.51M; member and professional programs. | Do not combine Foundation or PAC balances into operating revenue. |
| ACOG Foundation | Separate 501(c)(3), EIN 36-2217981. | FY2024 revenue $13.25M; assets $138.07M; net assets $135.21M; $1.5M grant to ACOG. | Foundation assets are not unrestricted College operating assets. |
| Ob-GynPAC | Separate federally registered membership-organization PAC. | Jan. 1, 2025–Jun. 30, 2026 receipts $907,675.61; disbursements $731,948.01; individual contributions $891,175.61. | Do not treat PAC receipts as ACOG operating revenue or member dues. |
| Federal lobbying | ACOG registers and reports lobbying separately under the Lobbying Disclosure Act. | Q4 2025 estimated lobbying expense $230,000; issues included maternal health, workforce, reproductive care, vaccination, and research. | Lobbying expense does not establish partisan control or candidate spending. |
| Publishing/advertising | Journal and website advertising operations include Wolters Kluwer contacts and stated editorial separation. | Advertising, list rental, exhibits, sponsorships, and corporate giving opportunities are documented. | A commercial relationship alone does not prove influence over guidance. |
| OpenEvidence collaboration | Strategic content/technology relationship announced May 4, 2026. | ACOG guidance is integrated for clinicians; ACOG may use query insights to inform future guidance and education. | Terms, payments, data governance, and influence cannot be inferred from the announcement. |
| Actor or institution | Influence classification | Evidence | Limit |
|---|---|---|---|
| Voting Fellow classes | Directly documented | Vote on national officer slate; eligible for national offices under published rules. | Turnout and demographic/practice composition not public. |
| Board of Directors | Directly documented | Provides governance; appoints/establishes committees and accepts officer slate. | Public bylaws not located for full authority mapping. |
| CEO and executive leadership | Directly documented | Oversee day-to-day operations, finance, legal, publishing, membership, clinical, and government affairs work. | Internal decision records generally not public. |
| ACOG Foundation | Directly documented | Related charitable entity, shared leaders, $1.5M FY2024 grant. | Grant restrictions and program-by-program influence not fully public. |
| Government funders | Directly documented historical relationship | $6.5M government grants in FY2024; ACOG reports withdrawal from all federal funding in 2025. | Agency and award mapping incomplete in this review; replacement funds unknown. |
| Publishers, advertisers, exhibitors, sponsors, licensees | Directly documented relationship; influence unknown | Advertising, sponsorship, royalty, exhibit, and list-rental channels exist. | No reliable evidence found that a commercial partner controls policy or guidance. |
| Ob-GynPAC and endorsed candidates | Directly documented political channel | Separate PAC with individual contributions and candidate/committee spending. | Political access is not equivalent to operational control of ACOG. |
| Stated commitment | Relevant action or omission | Assessment | Confidence |
|---|---|---|---|
| Support sustainable, fulfilling ob-gyn careers | Years of coding advocacy preceded AMA adoption of unbundled obstetric codes beginning Jan. 1, 2027. | Supported | High |
| Evidence-based clinical leadership | Maintains clinical guidance, released a 2026 maternal immunization schedule, and hired a CMO to oversee guidance/quality/practice. | Supported | High |
| Access to high-quality care | Advocates on maternal health, rural workforce, Medicaid, contraception, and reproductive care; OpenEvidence collaboration broadens clinician reach. | Supported | High |
| Independent recommendations | Withdrew from all federal funding in 2025, citing independence. | Supported | Moderate-high |
| Accessible clinical guidance | Beginning August 2026, full guidance is available through the journal or members-only app; nonmembers need membership or a journal subscription. | Partially supported | High |
| Member accountability and ethics | Grievance process and professional-misconduct policies exist; final disciplinary actions are available to voting Fellows rather than broadly public. | Partially supported | High |
| Financial independence and public trust | Required tax and political filings are public, but ultimate payer classes, sponsor amounts, royalty counterparties, and concentration remain incomplete. | Not fully demonstrated | High |
Mission-conflict status: minor. The record shows strong mission activity with tensions around access and disclosure; no severe, evidence-supported contradiction was found.
| Physician role | Signal | Strongest support | Strongest limit or contrary fact | Confidence | Sources |
|---|---|---|---|---|---|
| Individual ob-gyn | Supportive | Formal membership, voting, guidance, education, coding, and specialty advocacy. | Slate process; no public turnout or segment-vote data. | High | 134616 |
| Employed ob-gyn | Mixed | Clinical autonomy, payment, workforce, and burden advocacy. | Employer-paid dues may mediate payment; little public evidence on noncompetes or employment mobility. | Moderate | 2161730 |
| Independent/practice-owning ob-gyn | Supportive | Coding/payment reform and practice-management resources. | Actual payer implementation of new codes remains future and may vary. | Moderate-high | 16 |
| Physician executive/group leader | Supportive | Quality/safety programs, clinical standards, workforce and payment tools. | Quality in Action pricing, outcomes, and data terms were not public in reviewed sources. | Moderate | 151617 |
| Primary care/non-ob-gyn clinician | Mixed | OpenEvidence makes ACOG guidance easier to reach across specialties. | Secondary formal constituency; full-library access is journal/member gated from Aug. 2026. | Moderate-high | 31819 |
| Rural/community ob-gyn | Supportive | Rural workforce, NHSC, maternity-desert, and broad guidance-access advocacy. | Segment-specific outcomes and representation metrics are limited. | Moderate | 1718 |
| Academic physician | Supportive | Committee pathways, education, research, guidance development, and policy leadership. | Appointment competition and composition data are incomplete. | High | 56 |
| Trainee/early career | Supportive | Junior Fellow Board seats, committee eligibility, education, and leadership pathways. | Participation, voting, and career-outcome data are not public. | High | 56 |
| Issue | Signal | Evidence | Limit | Sources |
|---|---|---|---|---|
| Clinical guidance and education | Supportive | Large, expert-reviewed guidance and education portfolio. | Some full-text access is gated; outcomes of guidance adoption are not always public. | 11929 |
| Coding, payment, and sustainability | Supportive | New obstetric codes directly address payment fit and administrative burden. | Implementation and actual reimbursement effects begin in 2027. | 16 |
| Administrative burden | Supportive | Coding reform and policy advocacy target burden and workflow. | No comprehensive burden-reduction outcome dashboard found. | 1617 |
| Workforce, rural, and underserved care | Supportive | Federal workforce, rural access, maternal health, and safety advocacy. | Segment-level effect sizes are incompletely reported. | 1517 |
| Reproductive-care autonomy | Supportive for aligned clinicians | Consistent guidance, litigation, and advocacy for full-spectrum reproductive care and patient-clinician decision-making. | Policy positions may diverge from some members' ethical or political beliefs. | 11729 |
| Governance and professional voice | Mixed | Physician-led Board, elections, districts, and committees. | Current bylaws, turnout, and segment representation data not fully public. | 456 |
| Funding independence | Mixed | Federal-funding withdrawal and stated ad/editorial separation. | Most ultimate payer classes and commercial terms remain unknown. | 1112152021 |
| Employment mobility/noncompetes | Not demonstrated | No material current ACOG record was established in this scoped review. | Additional targeted policy research could change this label. | Scoped review of refs 1–30 |
| Practice ownership/consolidation | Unknown | No comprehensive current position/outcome was established in reviewed sources. | Do not infer neutrality from absence in this report. | Scoped review of refs 1–30 |
In Docket C-2855, ACOG entered a consent order concerning relative-value studies and fee-related guidance. The settlement was for resolution and did not constitute an admission of the charged violation. The order required ACOG to stop developing or promoting its own relative-value guides.
At ACOG's request, the FTC narrowed the restriction to allow broader communication with government and third-party payers, including reimbursement discussions, while retaining limits on ACOG-created relative-value guides and coercive negotiation.
Legal/regulatory/ethical score: 9/10, high evidence confidence. The historical order is material and disclosed here; current governance and ethics controls are documented, with public-discipline transparency limitations.
The numerical grade measures evidence quality, transparency, accountability, mission-to-action alignment, governance, legal record, and outcomes. It does not directly answer whether ACOG supports every physician, political view, or practice model.
| Dimension | Score | Why | Confidence |
|---|---|---|---|
| Financial transparency/source identification | 10/15 | Accurate tax categories and related entities are available, but ultimate payer identification is poor. | High |
| Funding independence/concentration | 7/15 | Federal withdrawal is favorable; concentration cannot be computed and commercial/dues payer mix is unknown. | Moderate |
| Mission-to-action alignment | 18/20 | Strong evidence across guidance, coding, education, workforce, maternal health, and advocacy; access/disclosure tensions remain. | High |
| Governance/representation | 13/15 | Physician-led voting, districts, committees, and trainee pathways; public bylaws/turnout/composition gaps. | High |
| Breadth across physician segments | 8/10 | Broad ob-gyn support and trainee/early-career structures; non-ob-gyn and segment outcome evidence is thinner. | Moderate-high |
| Leadership/conflicts/accountability | 8/10 | Current leaders and policies are public; detailed conflict disclosures and decision records are not broadly public. | Moderate-high |
| Legal/regulatory/ethical | 9/10 | Remote FTC consent order disclosed and later narrowed; current ethics systems documented. | High |
| Outcomes/public accountability | 4/5 | Concrete coding and policy outcomes exist; some program and segment effects are not quantified. | Moderate-high |
Evidence sources: All 30 references inform the rubric; the score is an interpretation produced by the stated methodology, not a source-provided rating.
Most program-service, contribution, royalty, sponsorship, exhibit, advertising, and employer-paid dues sources cannot be reconciled to payer classes.
National election turnout, delegate/committee composition by practice model, and segment-level member satisfaction were not located publicly.
The effect of the 2025 federal-funding withdrawal will not be clear until newer complete filings or audited statements are available.
Publication status: Public review. A last-link check and final editorial approval are required before each release.
Organization review: The reviewed organization did not approve, edit, or veto the score. A factual correction process is described on the Blair Compass methodology and corrections pages.
Scope: Verification is limited to publicly accessible records. Private contracts, nonpublic minutes, sealed proceedings, and undisclosed conflicts are outside the available evidence.
Source rule: Primary and official records were preferred. Accounting categories were not converted into payer identities. Related entities were kept separate. Allegations were not treated as findings.
Verification: current leaders and major financial arithmetic were checked for this publication batch. Material corrections and future updates follow the published verification process.
